



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



GSK329

Item No. 40666

CAS Registry No.: 1268490-12-5
Formal Name: N-[3,5-dichloro-4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]-N'-[3-(trifluoromethyl)phenyl]-urea
MF: C₁₉H₁₄Cl₂F₃N₅O₂
FW: 472.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK329 is supplied as a solid. A stock solution may be made by dissolving the GSK329 in the solvent of choice, which should be purged with an inert gas. GSK329 is sparingly soluble (1-10 mg/ml) in ethanol and DMSO.

Description

GSK329 is an inhibitor of cardiac troponin I-interacting kinase (TNNI3K; IC₅₀ = 10 nM) and a derivative of the multi-kinase inhibitor sorafenib (Item Nos. 10009644 | 35612).¹ It is selective for TNNI3K over VEGFR2, p38α, and B-RAF (IC₅₀s = 400, 800, and >2,000 nM, respectively). *In vivo*, GSK329 (2.75 mg/kg) reduces superoxide levels in isolated left ventricular tissues and infarct size in a mouse model of myocardial ischemia-reperfusion injury induced by left anterior descending (LAD) coronary artery occlusion.²

References

1. Patterson, J.R., Graves, A.P., Stoy, P., *et al.* Identification of diarylurea inhibitors of the cardiac-specific kinase TNNI3K by designing selectivity against VEGFR2, p38α, and B-Raf. *J. Med. Chem.* **64**(21), 15651-15670 (2021).
2. Vagnozzi, R.J., Gatto, G.J., Jr., Kallander, L.S., *et al.* Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. *Sci. Transl. Med.* **5**(207), 207ra141 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/15/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM